3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Interventions
pembrolizumab
35
Carboplatin
24
Specimen Handling
20
Cyclophosphamide
19
Magnetic Resonance Spectroscopy
18
fludarabine
15
Dexamethasone
15
Nivolumab
14
Gemcitabine
14
Bevacizumab
14
Biopsy
12
atezolizumab
11
Temozolomide
11
Paclitaxel
10
Docetaxel
10
Cisplatin
10
venetoclax
9
Rituximab
9
Pemetrexed
9
Ipilimumab
9
Prednisone
8
Lenalidomide
8
Fluorouracil
8
blinatumomab
7
Vincristine
7
Radiotherapy
7
Oxaliplatin
7
Capecitabine
7
olaparib
6
lenvatinib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
tafasitamab
×
30 days
×
Clear all
NCT04661007
2026-05-18
J-MIND
Incyte Corporation
Phase 1/2
Active not recruiting
72 enrolled